Medconn Showcases the Power of Global Diagnostics
At ADLM 2025, held in Chicago in July 2025, Medconn made a strong appearance with a portfolio of advanced diagnostic products. The booth attracted considerable attention from international visitors, showcasing the technological capabilities and growing global presence of Chinese IVD innovation.
From its flagship HbA1c solutions and advanced hematology analyzers to intelligent laboratory solutions, Medconn is accelerating its global expansion and demonstrating the growing international impact of Chinese innovation and manufacturing.
Product Highlights
At ADLM 2025, the Medconn booth welcomed a steady stream of international visitors interested in its expanding product portfolio. The exhibition highlighted Medconn's continued commitment to innovation, quality, and technological excellence.
Among the key highlights was the MQ Series HbA1c Analyzer, showcased in four models. In particular, the FDA 510(k)-cleared MQ-3000 attracted significant attention for its accurate and reliable HbA1c testing capabilities, as well as its broad applicability for hemoglobin variant and thalassemia screening.
Advanced Technology for Accurate Diagnostics
In addition to its HbA1c portfolio, Medconn showcased two 5-part differential hematology analyzers—the MH-60 and DX-80.
Both analyzers support immature granulocyte (IG) reporting and parasite-infected red blood cell (pRBC) detection, providing additional support for the screening and assessment of infectious diseases.
Medconn also presented its AI-assisted diagnostic software and Laboratory Information System (LIS) at the exhibition. These solutions further demonstrate Medconn's capabilities across the entire diagnostic ecosystem—from hardware and software to individual instruments and integrated laboratory solutions—helping laboratories move toward a smarter and more connected era of precision diagnostics.
Accelerating Global Expansion
From the Middle East and South America to North America, Medconn continues to strengthen its presence at major international IVD exhibitions around the world.
Its participation in ADLM 2025 in Chicago marks another important step in Medconn's international expansion, showcasing the technological confidence and solution capabilities of Chinese IVD companies to a global audience.
Looking ahead, Medconn will continue to deepen its presence in international markets, delivering high-quality diagnostic products and services to customers worldwide and sharing the precision, innovation, and human-centered approach of Chinese manufacturing and innovation with the global healthcare community.
